Onsite Tobacco Cessation Treatment for Patients With PAD
Study Details
Study Description
Brief Summary
Tobacco cessation treatment is needed for individuals with peripheral artery disease (PAD) to improve symptoms, lower cardiovascular risk, and prevent amputation. While such treatment is effective, many PAD patients do not receive cessation therapy. Participants will receive nicotine replacement therapy, counseling, and and complete questionnaires. We hypothesize that integrating tobacco cessation services into a dedicated PAD clinic (OU CVI Limb Preservation Clinic) can improve tobacco cessation rates and improve PAD-related health outcomes in this at risk population.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Other: Standard Care All participants will receive standard care by the Tobacco Treatment Research Program. This includes nicotine replacement therapy such as patches, gum, or lozenges, counseling by a Tobacco Treatment Specialist, and complete questionnaires. |
Behavioral: Tobacco Treatment Research Program Standard Care
Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
|
Outcome Measures
Primary Outcome Measures
- Biochemically confirmed abstinence [13 weeks post enrollment]
We will measure the biochemically-confirmed self-reported smoking cessation rate at 13 weeks post-enrollment (a cessation rate of ≥ 15-20% will be a sign of feasibility).
Secondary Outcome Measures
- Rate of enrollment [Duration of the study (approximately 6 months)]
We will measure the rate of enrollment over those approached to be in the study (≥ 25% enrolled will indicate feasibility).
Other Outcome Measures
- Improvements in PAD [Baseline to 13 weeks post enrollment]
We will evaluate improvements among participants based on their responses in surveys.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have diagnosed peripheral artery disease
-
Tobacco user
-
18 years of age or older
-
Willing/able to attend all study visits
-
Be able to read, speak, and understand English
Exclusion Criteria:
- Do not meet the specified inclusion criteria above
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | TSET Health Promotion Research Center | Oklahoma City | Oklahoma | United States | 73104 |
Sponsors and Collaborators
- University of Oklahoma
Investigators
- Principal Investigator: Darla E Kendzor, PhD, University of Oklahoma
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 12774